Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction (LIBerate-OLE)
Open-Label Extension Phase 3 Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With HoFH and HeFH, CVD, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction
Sponsor: LIB Therapeutics LLC
Listed as NCT04798430, this PHASE3 trial focuses on Cardiovascular Disease With Mention of Arteriosclerosis and Elevated Cholesterol and remains ongoing. Sponsored by LIB Therapeutics LLC, it has been updated 8 times since 2020, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Enrolling By Invitation PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Enrolling By Invitation PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Enrolling By Invitation PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2023 — Jul 2024 [monthly]
Enrolling By Invitation PHASE3
▶ Show 3 earlier versions
-
Sep 2021 — Apr 2023 [monthly]
Enrolling By Invitation PHASE3
-
May 2021 — Sep 2021 [monthly]
Enrolling By Invitation PHASE3
-
Apr 2021 — May 2021 [monthly]
Enrolling By Invitation PHASE3
First recorded
Dec 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LIB Therapeutics LLC
- Medpace, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .